Immunostaining for CD31 indicated that control tumors (sNef-M1 peptide treated) had well established vascularity, but Nef-M1 peptide treated tumors had poor vascularization for both CRC (Figure 3) and BC (Figure 4). This evidence concerns the gene S100B and breast cancer.